Clinuvel appoints non-executive director
22 January, 2015 by Dylan Bushell-EmblingClinuvel (ASX:CUV) has named B&S International founder William Blijdorp as a non-executive director, to help assist with the European commercialisation of Scenesse in erythropoietic protoporphyria.
Smart inhaler helps asthmatic kids breathe easier
22 January, 2015 by Dylan Bushell-EmblingA smart inhaler developed by Nexus6 improves medication adherence in child asthmatics and reduces their reliance on rescue medication.
Pharmaxis inflammatory disease drug enters phase I
22 January, 2015 by Dylan Bushell-EmblingPharmaxis (ASX:PXS) has kicked off a phase I single ascending dose study of PXS428A, an SSAO inhibitor with the potential to treat inflammatory diseases including non-alcoholic steatohepatitis.
Medical Developments close to Penthrox approval in UK
21 January, 2015 by Dylan Bushell-EmblingMedical Developments International (ASX:MVP) is close to securing approval from the UK's MHRA for its inhaled analgesic Penthrox.
CEOs' views sought on consultations: share schemes and equity crowd funding
20 January, 2015Among the proposals included in the October release of the federal government's Industry Innovation and Competitiveness Agenda (IICA) was a consultation on a potential regulatory framework for crowd-sourced equity funding (CSEF) in Australia and the tax treatment of employee share schemes (ESS), to be repaired after the 2009 changes saw companies flee the program.
Orthocell wins Chinese patent for Celgro
19 January, 2015 by Dylan Bushell-EmblingOrthocell (ASX:OCC) has been granted a Chinese patent for its Celgro collagen bio-scaffold platform technology, augmenting its IP protection in the APAC region.
Immuron recruiting patients for ASH trial
19 January, 2015 by Dylan Bushell-EmblingImmuron (ASX:IMC) has enrolled the first patients for a phase II trial of IMM-124E in alcoholic steatohepatitis and arranged to potentially license the drug candidate in alcohol-induced liver toxicity.
Novogen claims brain regeneration breakthrough
16 January, 2015 by Dylan Bushell-EmblingNovogen (ASX:NRT) has identified a family of compounds with the potential to promote the growth and activity of stem cells in injured parts of the brain.
Low dollar tipped to stimulate biotech investment
15 January, 2015Analyst commentary suggests the devaluation of the Australian dollar during 2014 has left biotech in a good position for investment, as well as a target for takeovers and mergers.
Mesoblast MPCs improve back pain in phase II trial
15 January, 2015 by Dylan Bushell-EmblingMesoblast (ASX:MSB) has presented data from its phase II trial of MPCs in lower back pain and initiated a phase III program on the strength of the results.
Start-up seeks to improve stability of antibodies
15 January, 2015 by Dylan Bushell-EmblingSolvanix, an Australian start-up commercialising a technology to improve the stability and reduce side effects associated with antibody therapies, launched today with $2m in MCRF funding.
Phosphagenics names new CEO
14 January, 2015 by Dylan Bushell-EmblingPhosphagenics (ASX:POH) has appointed Dr Ross Murdoch as its new CEO and has received ethics approval for a pilot trial of TPM/Oxycodone in post-herpetic neuralgia.
Join us in our New Year's resolutions to grow the biotech industry
13 January, 2015The time is here to list AusBiotech's New Year's resolutions, which will buoy and grow the Australian biotechnology industry, support your success and ensure 2015 is the best year yet.
CNS establishes US operations
09 January, 2015 by Dylan Bushell-EmblingConsulting company Clinical Network Services (CNS) has established an office in the US to allow it to support clients seeking to engage with the FDA.
Graeme Clark wins Russ Prize for cochlear implant
08 January, 2015 by Dylan Bushell-EmblingProfessor Graeme Clark and four international scientists have jointly won the biennial US$500,000 Russ Prize for their contributions to the developing the cochlear implant.
